Delving into the Latest Updates on Sagopilone with Synapse

Overview

Basic Info

Drug Type

Small molecule drug

Synonyms

Sagopilone (USAN/INN), ZK epothilone, ZK-EPO

+ [9]

Target

Tubulin

Action

modulators, inhibitors

Mechanism

Tubulin modulators, Mitosis inhibitors, Tubulin polymerisation promoters

Therapeutic Areas

NeoplasmsNervous System DiseasesEndocrinology and Metabolic Disease+ [3]

Active Indication-

Inactive Indication

Advanced breast cancerBrain metastasesBreast Cancer+ [11]

Originator Organization

Bayer AG

Active Organization-

Inactive Organization

Bayer AGLaboratoires Thissen SA

Schering AG

License Organization-

Drug Highest PhaseDiscontinuedPhase 2

First Approval Date-

Regulation-

Login to view timeline

Structure/Sequence

Molecular FormulaC30H41NO6S

InChIKeyBFZKMNSQCNVFGM-UCEYFQQTSA-N

CAS Registry305841-29-6

This study investigates the safety and efficacy of Acetyl-L-Carnitine and compares it to the safety and efficacy of a placebo (inactive) tablet in the prevention of Sagopilone-induced peripheral neuropathy. Patients will receive intravenous infusion of sagopilone for 3 hours on day 1 of a 3-weeks cycle. Treatment with Sagopilone will be given as long as the patient is benefitting. In addition patients will receive ALC or placebo, starting 1 week before first sagopilone infusion and ending 30-33 days after the last infusion with sagopilone. Safety will be determined by laboratory and other evaluations. Efficacy of ALC will be determined by the incidence of all grades of peripheral neuropathy with the results of a patient questionnaire. Efficacy of the combination of ALC and Sagopilone will be determined by the tumor response.

Start Date01 Aug 2008

Sponsor / Collaborator

Bayer AG

EUCTR2008-001494-15-DE

/ Not yet recruitingNot Applicable

Phase I/II Study of Sagopilone in combination with carboplatin and bevacizumab in the first-line treatment of patients with stage IIIB/IV,non-squamous NSCLC.

Start Date08 Jul 2008

Sponsor / Collaborator-

NCT00496379

/ TerminatedPhase 2IIT

A Phase 2 Study of ZK219477 (ZK-EPO) in Patients With Breast Cancer and Brain Metastases

The purpose of this research study is to determine the effects (good and bad) of ZK219477(sagopilone) on participants and their cancer. ZK219477 is a chemotherapy drug that is thought to work by interfering with the ability of cancer cells to grow and divide. It is a part of a group of drugs called "epothilones" which appear to cause shrinkage of cancer in some patients with breast cancer. It is generally difficult for chemotherapy to enter the brain. However, it is believed that ZK219477 crosses into the brain. We are also studying whether an investigational MRI scan procedure may eventually help to predict which patients will benefit from ZK219477.

Start Date01 Jul 2007

Sponsor / Collaborator

Dana-Farber Cancer Institute, Inc.

[+3]

100 Clinical Results associated with Sagopilone

Login to view more data

100 Translational Medicine associated with Sagopilone

Login to view more data

100 Patents (Medical) associated with Sagopilone

Login to view more data

80

Literatures (Medical) associated with Sagopilone

21 Oct 2024·Angewandte Chemie

A Photocaged Microtubule‐Stabilising Epothilone Allows Spatiotemporal Control of Cytoskeletal Dynamics

Author: Akhmanova, Anna ; Vepřek, Nynke A. ; Schmitt, Carina ; Meiring, Joyce C. M. ; Dehmelt, Leif ; Gierse, Carolin ; Kuch, Jürgen ; Mauker, Philipp ; Thorn‐Seshold, Oliver

AbstractThe cytoskeleton is essential for spatial and temporal organisation of a wide range of cellular and tissue‐level processes, such as proliferation, signalling, cargo transport, migration, morphogenesis, and neuronal development. Cytoskeleton research aims to study these processes by imaging, or by locally manipulating, the dynamics and organisation of cytoskeletal proteins with high spatiotemporal resolution: which matches the capabilities of optical methods. To date, no photoresponsive microtubule‐stabilising tool has united all the features needed for a practical high‐precision reagent: a low potency and biochemically stable non‐illuminated state; then an efficient, rapid, and clean photoresponse that generates a high potency illuminated state; plus good solubility at suitable working concentrations; and efficient synthetic access. We now present CouEpo, a photocaged epothilone microtubule‐stabilising reagent that combines these needs. Its potency increases approximately 100‐fold upon irradiation by violet/blue light to reach low‐nanomolar values, allowing efficient photocontrol of microtubule dynamics in live cells, and even the generation of cellular asymmetries in microtubule architecture and cell dynamics. CouEpo is thus a high‐performance tool compound that can support high‐precision research into many microtubule‐associated processes, from biophysics to transport, cell motility, and neuronal physiology.

01 Jul 2024·Ecotoxicology and Environmental Safety

Protective effects of Abrus cantoniensis Hance against liver injury through modulation of intestinal microbiota and liver metabolites

Article

Author: Li, Kun ; Sun, Jingyi ; Kulyar, Muhammad Fakhar-E-Alam ; Xu, Chang ; Li, Xiaocong ; Iqbal, Mujahid ; Wu, Yi ; Fouad, Dalia ; Ali, Munwar

Abrus cantoniensis Hance (ACH) is an ancient Chinese medicine herb known for its therapeutic effects. This study investigated the potential protective effect of ACH against carbon tetrachloride (CCl₄)-induced liver damage in mice. Fifty (n= 50) ICR mice were grouped into five groups. CCl₄ was intraperitoneally injected into different mice groups: AM (CCl₄ induced), AD (ACH-treated with 25 mg/kg), AZ (ACH-treated with 50 mg/kg), and AG (ACH-treated with100mg/kg) after every three days for a total of 31 days. The control group was denoted as AC. Additionally, groups AD, AZ, and AG received daily doses of ACH via gavage throughout the study period. According to our findings, ACH administration prominently mitigated liver pathological lesions and the increased liver index induced by CCl₄ in mice (p < 0.05). Treatment with ACH resulted in a dose-dependent recovery of GSH-px, SOD, and CAT activities (p < 0.001). Moreover, the levels of TNF-α, MDA, and ALT showed significanlty decreasing trends with various doses of ACH (p < 0.001). Furthermore, 16 S rRNA gene sequencing demonstrated that ACH increased the abundance of beneficial genera of Comoclathris, Aureobasidium, and Kazachstania while decreased the presence of pathogenic genera such as Sporobolomyces and Filobasidium. Additionally, ACH treatment ameliorated the changes in liver metabolism due to CCl₄ and enhanced the beneficial liver metabolites. In conclusion, ACH shows potential in protecting the liver against oxidative stress and inflammation caused by CCl₄ exposure, possibly through its effects on gut microbiota and liver metabolism. Therefore, the use of ACH may offer an effective approach for alleviating CCl₄-induced liver injury.

27 Apr 2023·Scientific reports

A novel Alzheimer's disease prognostic signature: identification and analysis of glutamine metabolism genes in immunogenicity and immunotherapy efficacy.

Article

Author: Deng, Sisi ; Song, Zhenyan ; Huang, Baisheng ; Huang, Xindi ; Wu, Zixuan ; Yang, Jing ; Cheng, Shaowu ; Liu, Ping

Alzheimer's disease (AD) is characterized as a distinct onset and progression of cognitive and functional decline associated with age, as well as a specific neuropathology. It has been discovered that glutamine (Gln) metabolism plays a crucial role in cancer. However, a full investigation of its role in Alzheimer's disease is still missing. This study intended to find and confirm potential Gln-related genes associated with AD using bioinformatics analysis. The discovery of GlnMgs was made possible by the intersection of the WGCNA test and 26 Gln-metabolism genes (GlnMgs). GlnMgs' putative biological functions and pathways were identified using GSVA. The LASSO method was then used to identify the hub genes as well as the diagnostic efficiency of the four GlnMgs in identifying AD. The association between hub GlnMgs and clinical characteristics was also studied. Finally, the GSE63060 was utilized to confirm the levels of expression of the four GlnMgs. Four GlnMgs were discovered (ATP5H, NDUFAB1, PFN2, and SPHKAP). For biological function analysis, cell fate specification, atrioventricular canal development, and neuron fate specification were emphasized. The diagnostic ability of the four GlnMgs in differentiating AD exhibited a good value. This study discovered four GlnMgs that are linked to AD. They shed light on potential new biomarkers for AD and tracking its progression.

100 Deals associated with Sagopilone

Login to view more data

External Link

KEGG	Wiki	ATC	Drug Bank
D09721	-	-	DB12391

R&D Status

10 top R&D records.

Login

to view more data

Indication	Highest Phase	Country/Location	Organization	Date
Metastatic breast cancer	Phase 2	Italy	Bayer AG	01 Dec 2005
Metastatic breast cancer	Phase 2	United Kingdom	Bayer AG	01 Dec 2005
Metastatic breast cancer	Phase 2	Poland	Bayer AG	01 Dec 2005
Metastatic breast cancer	Phase 2	France	Bayer AG	01 Dec 2005
Metastatic breast cancer	Phase 2	Germany	Bayer AG	01 Dec 2005
Metastatic breast cancer	Phase 2	Austria	Bayer AG	01 Dec 2005
Metastatic breast cancer	Phase 2	Bulgaria	Bayer AG	01 Dec 2005
Metastatic breast cancer	Phase 2	Slovenia	Bayer AG	01 Dec 2005
Recurrent ovarian cancer	Phase 2	-	Bayer AG	01 Nov 2005
Non-squamous non-small cell lung cancer	Phase 2	Germany	Bayer AG	01 Aug 2005

Login to view more data

Clinical Result

Indication

Phase

Evaluation

View All Results

Study	Phase	Population	Analyzed Enrollment	Group	Results	Evaluation	Publication Date


NCT00598507 (CTgov)	Phase 2	Metastatic melanoma	35	ZK-EPO	igdjckywnx(igeigmxvab) = vfxchlmtuu bsxwrtfcnc (kouneqajfz, czksphdcnl - gbbbnekfqg) View more	-	15 Nov 2013
Pubmed \| Br J Cancer	Phase 2	Castration-Resistant Prostatic Cancer First line prostate-specific antigen	53	Sagopilone plus prednisone	anbmjnlpht(uqwrhfnymv) = 54.7% of patients experienced fatigue hlqztzoijz (klhaxsrdvn ) View more	Positive	01 Aug 2012
NCT00246688 (Pubmed \| Ann Oncol)	Phase 2	Platinum-Resistant Ovarian Carcinoma	63	Sagopilone 16 mg/m(2) as a 3-h infusion	(eccfcbrdik) = eucezzefni iotespcvfr (xyfrhcffvx ) View more	Positive	01 Nov 2011
NCT00246688 (Pubmed \| Ann Oncol)	Phase 2	Platinum-Resistant Ovarian Carcinoma	63	Sagopilone 16 mg/m(2) as a 0.5-h infusion	(eccfcbrdik) = ugjelqhesm iotespcvfr (xyfrhcffvx ) View more	Positive	01 Nov 2011
NCT00424060 (Pubmed \| Ann Oncol)	Phase 2	Recurrent Glioblastoma	38	Sagopilone	(ykidxbsqga) = gttxnjnoqz kgsnxcxtbs (khadaidnff ) View more	Negative	01 Sep 2011
NCT00397072 (Pubmed \| J Neurooncol)	Phase 2	Recurrent Malignant Glioma	15	ZK-EPO	(mahivxaatk) = whmwhvettj ahhkktbukr (kfvtuvvqwg )	-	01 Oct 2009
ASCO2009	Phase 2	Metastatic breast cancer	65	Sagopilone 16 mg/m2	(nippaixvhq) = 22% (5% grade 3) iavnkkcnyy (swhfclwjpr ) View more	-	20 May 2009
ASCO2009	Phase 2	Metastatic breast cancer	65	Sagopilone 22 mg/m2		-	20 May 2009
ASCO2009	Phase 2	Metastatic castration-resistant prostate cancer First line	53	Sagopilone 16 mg/m2	dqyazazwje(adxlusvcsu) = bxkeukjtbw gdhktmmeou (pcvmfuuzob, 32% - 52%) View more	-	20 May 2009
ASCO2008	Phase 1	Extensive stage Small Cell Lung Cancer First line	16	Sagopilone + Cisplatin	(yahcarkscu) = woomoutnvz seqpfjtmbl (dallpymgap ) View more	-	20 May 2008
ASCO2008	Phase 2	Recurrent Malignant Glioma	15	Sagopilone (16 mg/m2)	mnywzigoia(rgxmvmjbwr) = Grade 3/4 peripheral neuropathy occurred in 4 pts, with 1 requiring morphine treatment for neuropathy affecting their activities ogzlpvatmh (glebdnhyky ) View more	-	20 May 2008
ASCO2008	Phase 2	Metastatic Prostate Carcinoma First line	29	Sagopilone 16 mg/m2	(azxndgostm) = ocicwwcgoo zoinnlzcsm (bdistflvfe, 37–78) View more	-	20 May 2008